Antiemetic medications for preventing chemotherapy-induced nausea and vomiting in children: a systematic review and Bayesian network meta-analysis.
Antiemetics
Children
Evidence synthesis
Nausea and vomiting
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957
Informations de publication
Date de publication:
27 Oct 2024
27 Oct 2024
Historique:
received:
17
07
2024
accepted:
10
10
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
epublish
Résumé
Children continue to experience chemotherapy-induced nausea and vomiting (CINV), despite effective antiemetic medications. Recommendations in clinical practice guidelines are underpinned by narrative syntheses and meta-analyses that compare only two treatments. This means not all antiemetics have been compared to one another, and estimates remain imprecise. We apply network meta-analysis (NMA) to overcome these limitations by comparing multiple treatments simultaneously. A systematic review identified and critically appraised RCTs comparing antiemetics recommended and licensed for the prevention of CINV in children. Bayesian NMA compared and ranked antiemetic effectiveness for the outcomes complete (CR) and partial response (PR) in the acute, delayed, and overall phases, nausea, and decreased food intake. Antiemetics given with and without dexamethasone were compared in separate networks as their underlying populations differed. Sixteen RCTs (3115 patients receiving moderately (MEC) or highly emetogenic chemotherapy (HEC)) were included. When given with dexamethasone, NK1 antagonists with ondansetron ranked highest for CR and PR in the acute and overall phases, PR in the delayed phase, and decreased food intake. Post hoc analysis shows further a benefit of adding olanzapine to regimens of aprepitant and ondansetron. Ondansetron ranked lower than palonosetron, for CR in the delayed and overall phases, and ondansetron was less effective than palonosetron for nausea prevention. Rankings for other regimens, including those given without dexamethasone, were uncertain or inconsistent across outcomes. Our findings serve to support the current recommendations of olanzapine (when given with aprepitant and ondansetron) and NK1 antagonists' regimens receiving HEC, but note that evidence of a significant difference in relative benefit, between patients receiving MEC and HEC, does not yet exist. Recommendations for palonosetron as the preferred 5HT3 antagonists may be extended, particularly, to those who are at high risk of nausea.
Identifiants
pubmed: 39465444
doi: 10.1007/s00520-024-08939-9
pii: 10.1007/s00520-024-08939-9
doi:
Substances chimiques
Antiemetics
0
Antineoplastic Agents
0
Dexamethasone
7S5I7G3JQL
Types de publication
Journal Article
Systematic Review
Meta-Analysis
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
747Subventions
Organisme : National Institute of Health and social care Research (NIHR)
ID : NIHR302291
Informations de copyright
© 2024. The Author(s).
Références
Hedström M, Haglund K, Skolin I, von Essen L (2003) Distressing events for children and adolescents with cancer: child, parent, and nurse perceptions. J Pediatr Oncol Nurs 20:120–32
doi: 10.1053/jpon.2003.76
pubmed: 12776260
Phillips RS, Gibson F, Houghton E, Gopaul S, Craig JV, Pizer B (2016) Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood (an update). Cochrane Database Syst Rev 2(2). https://doi.org/10.1002/14651858.CD007786.pub3
Chang T (2015) Nausea and vomiting. Supportive care in pediatric oncology: a practical evidence-based approach, 1st edn. Springer Berlin Heidelberg Imprint Springer, pp 159–175
doi: 10.1007/978-3-662-44317-0_10
Paw Cho Sing E, Robinson PD, Flank J, Holdsworth M, Thackray J, Freedman J, Gibson P, Orsey AD, Patel P, Phillips R, Portwine C, Raybin JL, Cabral S, Sung L, Dupuis LL (2019) Classification of the acute emetogenicity of chemotherapy in pediatric patients: a clinical practice guideline. Pediatr Blood Cancer 66(5):e27646
doi: 10.1002/pbc.27646
pubmed: 30729654
Patel P, Robinson, PD, Cohen, M et al (2022) Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: a clinical practice guideline. Pediatr Blood Cancer 69. https://doi.org/10.1002/pbc.30001
Patel P, Robinson PD, Devine KA, Positano K, Cohen M, Gibson P, Holdsworth M, Phillips R, Spinelli D, Thackray J, van de Wetering M, Woods D, Cabral S, Sung L, Dupuis LL (2021) Prevention and treatment of anticipatory chemotherapy-induced nausea and vomiting in pediatric cancer patients and hematopoietic stem cell recipients: clinical practice guideline update. Pediatr Blood Cancer 68. https://doi.org/10.1002/pbc.28947
Patel P RP, Thackray J, Flank J, Holdsworth MT, Gibson P et al (2017) Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update. Pediaticr Blood Cancer 64. https://doi.org/10.1002/pbc.26542
Dupuis LLSL, Molassiotis A, Orsey AD, Tissing W, van de Wetering M (2017) MASCC/ESMO consensus recommendations: prevention of acute chemotherapy-induced nausea and vomiting in children. 2017(25):323-31
CCLG CsCaLG (2018) Guideline on the management of chemotherapy induced nausea and vomiting. Available from: https://www.piernetwork.org/uploads/4/7/8/1/47810883/cclg_cinv_guideline_march_2018.pdf . Accessed Aug 2024
Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA et al (2020) Antiemetics: ASCO guideline update. J Clin Oncol 38(24):2782–2797
doi: 10.1200/JCO.20.01296
pubmed: 32658626
Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA et al (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35(28):3240–3261
doi: 10.1200/JCO.2017.74.4789
pubmed: 28759346
Dupuis LLBS, Sung L, Portwine C, Hain R, McCarthy P, Holdsworth M, Pediatric Oncology Group of Ontario (2011) Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer 57(2):191–8
doi: 10.1002/pbc.23114
pubmed: 21465637
Phillips RS, Gopaul S, Gibson F, Houghton E, Craig JV, Light K et al (2010) Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Cochrane Database Syst Rev 9:CD007786
Crane SBM (2017) Understanding ethical issues of research participation from the perspective of participating children and adolescents: a systematic review. Worldviews Evid Based Nurs 14(3):200–209
doi: 10.1111/wvn.12209
pubmed: 28207982
pmcid: 5724520
Bloomfield F (2015) The challenges of research participation by children. Pediatr Res 78:109–110
doi: 10.1038/pr.2015.75
pubmed: 25923012
Peake JNBE, Oostendorp LJM et al (2022) Research barriers in children and young people with life-limiting conditions: a surve. BMJ Support Palliat Care 12:e715–e721
doi: 10.1136/bmjspcare-2018-001521
pubmed: 30065044
Dias SWN, Jansen JP, Sutton A (2018) Network meta-analysis for decision making. Wiley
doi: 10.1002/9781118951651
Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777–784
doi: 10.7326/M14-2385
pubmed: 26030634
Rohatgi A (2022) WebPlotDigitizer version 4.6. Available from: https://automeris.io/WebPlotDigitizer . Accessed Aug 2024
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366. https://doi.org/10.1136/bmj.l4898
Rhodes KM, Turner RM, Higgins JP (2016) T Empirical evidence about inconsistency among studies in a pair-wise meta-analysis. Res Syn Meth 7:346–370
doi: 10.1002/jrsm.1193
Forni C, Ferrari S, Loro L, Mazzei T, Beghelli C, Biolchini A, Simoni P, Tremosini M, Strazzari S, Puggioli C, Bacci G (2000) Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions. Support Care Cancer 8:131–133
doi: 10.1007/s005200050027
pubmed: 10739360
Koseoglu V, Kurekci AE, Sarici U, Atay AA, Ozcan O (1998) Comparison of the efficacy and side-effects of ondansetron and metoclopramide-diphenhydramine administered to control nausea and vomiting in children treated with antineoplastic chemotherapy: a prospective randomized study. Eur J Pediatr 157:806–810
doi: 10.1007/s004310050940
pubmed: 9809818
Luisi FA, Petrilli AS, Tanaka C, Caran EM (2006) Contribution to the treatment of nausea and emesis induced by chemotherapy in children and adolescents with osteosarcoma. Sao Paulo Med J 124:61–65
doi: 10.1590/S1516-31802006000200003
pubmed: 16878187
pmcid: 11060355
Sepulveda-Vildosola AC, Betanzos-Cabrera Y, Lastiri GG, Rivera-Marquez H, Villasis-Keever MA, Del Angel VW et al (2008) Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Res 39(6):601–606
doi: 10.1016/j.arcmed.2008.04.007
pubmed: 18662592
Alvarez O, Freeman A, Bedros A, Call SK, Volsch J, Kalbermatter O, Halverson J, Convy L, Cook L, Mick K et al (1995) Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. J Pediatr Hematol Oncol 17:145–150
doi: 10.1097/00043426-199505000-00008
pubmed: 7749764
Berrak SG, Ozdemir N, Bakirci N, Turkkan E, Canpolat C, Beker B et al (2007) A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy. Support Care Cancer 15(10):1163–1168
doi: 10.1007/s00520-007-0242-y
pubmed: 17372773
Cakir FB, Yapar O, Canpolat C, Akalin F, Berrak SG (2012) Cardiac effects of granisetron in a prospective crossover randomized dose comparison trial. Support Care Cancer 20(10):2451–2457
doi: 10.1007/s00520-011-1376-5
pubmed: 22241602
Jaing TH, Tsay PK, Hung IJ, Yang CP, Hu WY (2004) Single-dose oral granisetron versus multidose intravenous ondansetron for moderately emetogenic cyclophosphamide-based chemotherapy in pediatric outpatients with acute lymphoblastic leukemia. Pediatr Hematol Oncol 21(3):227–235
doi: 10.1080/08880010490427351
pubmed: 15202162
Komada Y, Matsuyama T, Takao A, Hongo T, Nishimura Y, Horibe K, Sakurai M (1999) A randomised dose-comparison trial of granisetron in preventing emesis in children with leukaemia receiving emetogenic chemotherapy. Eur J Cancer 35:1095–1101
doi: 10.1016/S0959-8049(99)00071-4
pubmed: 10533454
Patil V, Prasada H, Prasad K, Shenoy UV (2015) Comparison of antiemetic efficacy and safety of palonosetron vs ondansetron in the prevention of chemotherapy-induced nausea and vomiting in children. J Community Support Oncol 13(6):209–213
doi: 10.12788/jcso.0139
pubmed: 26270519
Stiakaki E, Savvas S, Lydaki E, Bolonaki I, Kouvidi E, Dimitriou H et al (1999) Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy. Pediatr Hematol Oncol 16(2):101–108
doi: 10.1080/088800199277425
pubmed: 10100270
Eghbali A, Kohpar FK, Ghaffari K, Afzal RR, Eghbali A, Ghasemi A (2023) Evaluating aprepitant single-dose plus granisetron and dexamethasone in children receiving highly emetogenic chemotherapy for the prevention of chemotherapy-induced nausea and vomiting: a triple-blinded randomized clinical trial. Hematol Transfus Cell Ther 45(3):281–289
doi: 10.1016/j.htct.2022.02.004
pubmed: 35428609
Tsuchida Y, Hayashi Y, Asami K, Yamamoto K, Yokoyama J, Mugishima H, Honna T, Mimaya J, Hara F, Sawada T, Matsumura T, Suita S, Sugimoto T, Kaneko M (1999) Effects of granisetron in children undergoing high-dose chemotherapy: a multi-institutional, cross-over study. Int J Oncol 14:673–679
pubmed: 10087313
Brock P, Brichard B, Rechnitzer C, Langeveld NE, Lanning M, Soderhall S, Laurent C (1996) An increased loading dose of ondansetron: a North European, double-blind randomised study in children, comparing 5 mg/m2 with 10 mg/m2. Eur J Cancer 32:1744–1748
doi: 10.1016/0959-8049(96)00157-8
Sandoval C, Corbi D, Strobino B, Fevzi Ozkaynak M, Tugal O, Jayabose S (1999) Randomized double-blind comparison of single high-dose ondansetron and multiple standard-dose ondansetron in chemotherapy-naive pediatric oncology patients. Cancer Invest 17(5):309–313
doi: 10.3109/07357909909032871
pubmed: 10370357
Ruktrirong J, Traivaree C, Monsereenusorn C, Photia A, Lertvivatpong N, Rujkijyanont P (2021) Single daily dosing versus divided dosing intravenous ondansetron to prevent chemotherapy-induced nausea and vomiting among children: a comparative randomized double-blind controlled trial. Pediatr Blood Cancer 68(6):e29002
doi: 10.1002/pbc.29002
pubmed: 33754455
White L, Daly SA, McKenna CJ, Zhestkova N, Leal C, Breatnach F et al (2000) A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy. Pediatr Hematol Oncol 17(6):445–455
doi: 10.1080/08880010050120791
pubmed: 10989464
Dupuis LLTG, Pong A, Sung L, Bickham K, A Pooled Anal (2020) Factors associated with chemotherapy-induced vomiting control in pediatric patients receiving moderately or highly emetogenic chemotherapy: a pooled analysis. J Clin Oncol 1(22):2499–509
doi: 10.1200/JCO.20.00134
Kang HJ, Loftus S, Taylor A, DiCristina C, Green S, Zwaan CM (2015) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial. Lancet Oncol 16(4):385–394
doi: 10.1016/S1470-2045(15)70061-6
pubmed: 25770814
BMJ. British National Formulary (online) London. Joint Formulary Committee. British National Formulary: BMJ and pharmaceutical Press. Available from: http://www.medicinescomplete.com Accessed Aug 2024
Sra MS, Ganguly S, Naik RD, Sasi A, Sharma P, Giri RK et al (2023) Olanzapine cost-effectiveness in vomiting and nausea from highly emetogenic chemotherapy in children and adolescents. BMJ Support Palliat Care. https://doi.org/10.1136/spcare-2022-004069
NICE (2024) British National Formulary (BNF). Available from: https://bnf.nice.org.uk/drugs/palonosetron/medicinal-forms/. Accessed Aug 2024
Sra MS, Ganguly S, Sasi A, Sharma P, Giri RK, Rasheed AA et al (2022) Cost-effectiveness analysis of aprepitant-based anti-emetic regimen for children receiving highly emetogenic chemotherapy: individual patient data analysis of a randomized trial. Pediatr Blood Cancer 69(10):e29795
doi: 10.1002/pbc.29795
pubmed: 35652531